Status:
TERMINATED
Nutraceutical Efficacy for rUTI
Lead Sponsor:
Washington University School of Medicine
Conditions:
Urinary Tract Infections
Eligibility:
FEMALE
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
This is a study designed to evaluate the efficacy of a nutraceutical as a non-antibiotic treatment to prevent recurrent urinary tract infections in women that have completed menopause and are on vagin...
Detailed Description
The objective of this study is to determine the efficacy of a nutraceutical as a non-antibiotic prophylaxis for postmenopausal women on vaginal estrogen therapy (VET) with a history of symptomatic, cu...
Eligibility Criteria
Inclusion
- For the RCT arms of the study, the following inclusion criteria will apply:
- a. Postmenopausal women with recurrent UTI
- i. Recurrent UTI defined as:
- ≥ 2 symptomatic, culture-proven UTI in 6 months OR
- ≥ 3 symptomatic, culture-proven UTI in 12 months
- ii. Postmenopausal defined as no menses for at least 12 months or surgical menopause
- b. At least one documented prior uropathogen susceptible to D-mannose
- c. Using VET for a minimum of four weeks prior to study day 1
- Inclusion criteria for the Observational arm of the study are the same with the exception of item 'c.' above (using VET for a minimum of four weeks) as participants will not be on vaginal estrogen therapy.
Exclusion
- For the RCT arms of the study, the exclusion criteria are as follows:
- Not postmenopausal
- Currently on daily antibiotic UTI prophylaxis (If this is the only exclusion criteria met, a woman could be cleared for inclusion in study/enrollment after a 2 week washout period occurs prior to inclusion in the study (RCT or Observational arm))
- Complicated UTIs (known renal tract anomaly, inability to empty bladder due to neurologic causes, performs self-catheterization or has an indwelling catheter)
- Patients with incomplete bladder emptying (defined as post void residual \> 150 cc when minimal voided volume is \>150 cc)
- Known contraindication to VET unless approved by patient's oncologist, oncologic surgeon, or primary care physician (History of or current endometrial cancer; History of estrogen sensitive breast cancer without approval of patient, patient's oncologist, oncologic surgeon, or primary care physician to use vaginal estrogen after counseling)
- History of interstitial cystitis/painful bladder syndrome
- Urothelial cancer
- Non-English speaking
- Enrolled in other clinical trials for UTIs
- Currently using D-mannose or Methenamine for UTI prevention
- Exclusion criteria for the Observational arm of the study are the same with the exception of item 'e.' above (known contraindication to VET) as participants will not be on vaginal estrogen therapy.
Key Trial Info
Start Date :
March 22 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 25 2020
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT03395288
Start Date
March 22 2018
End Date
April 25 2020
Last Update
February 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110